The assay can provide results in less than four hours. Credit: CDC on Unsplash.

Genomics multiplexing platform company ChromaCode has commercially introduced the High Definition PCR (HDPCR)-based non-small-cell lung cancer (NSCLC) assay.

Leveraging amplitude modulation and multi-spectral encoding, the assay panel identifies actionable NSCLC variants in nine relevant genes from only low-sample input.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Claiming to offer cloud-based analysis and reduce workflow complexity, the assay can generate results in less than four hours.

HDPCR technology is an advanced method that enables the multiplexing of actionable biomarkers in a single, fast and cost-effective assay for different sample types on standard laboratory dPCR platforms. It has applications in oncology, organ transplant monitoring and other genomic areas.

ChromaCode Cloud complements HDPCR by delivering valuable insights and improving lab performance.

Serving as an integrated platform, this cloud-based solution is claimed to enable seamless result analysis, secure data management and efficient reporting.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ChromaCode CEO Mark McDonough said: “The ChromaCode team is committed to positively impacting both the survival rates and the quality of life of the patients that we are privileged to serve.

“We endeavour to do this by providing our physician and laboratory partners with high quality, fast, lower cost solutions such as the ChromaCode HDPCR NSCLC assay to expand options for faster, targeted treatment.”

The most common cancer of the lung, NSCLC constitutes approximately 85% of the over 230,000 annual lung cancer diagnoses in the US per annum and the five-year survival rate stands at 25.4%, as per the National Cancer Institute.